Zhang Xiang-Hua, He Jun-Hua, Zhang Xiang-Sheng, Zhang Jing, Wang Cheng-Jun, Dong Yi-Peng, Tao Wu
Department of Neurosurgery, Beijing Friendship Hospital Affiliated With Capital Medical University, Beijing, China.
Department of Neurosurgery, Zhejiang Provincial Tongde Hospital, Hangzhou, China.
Front Neurol. 2023 Jun 2;14:1169440. doi: 10.3389/fneur.2023.1169440. eCollection 2023.
The optimal treatment approach for hemorrhagic moyamoya disease (HMMD) remains a topic of debate, particularly regarding the comparative efficacy of revascularization versus conservative treatment. Our study, which included a single-center case series and a systematic review with meta-analysis, aimed to determine whether surgical revascularization is associated with a significant reduction in postoperative rebleeding, ischemic events, and mortality compared to conservative treatment among East Asian HMMD patients.
We conducted a systematic literature review by searching PubMed, Google Scholar, Wanfang Med Online (WMO), and the China National Knowledge Infrastructure (CNKI). The outcomes of surgical revascularization and conservative treatment, including rebleeding, ischemic events and mortality, were compared. The authors' institutional series of 24 patients were also included and reviewed in the analysis.
A total of 19 East Asian studies involving 1,571 patients as well as our institution's retrospective study of 24 patients were included in the study. In the adult patients-only studies, those who underwent revascularization had significantly lower rates of rebleeding, ischemic events, and mortality compared to those who received conservative treatment (13.1% (46/352) vs. 32.4% (82/253), < 0.00001; 4.0% (5/124) vs. 14.9% (18/121), = 0.007; and 3.3% (5/153) vs. 12.6% (12/95), = 0.01, respectively). In the adult/pediatric patients' studies, similar statistical results of rebleeding, ischemic events, and mortality have been obtained (70/588 (11.9%) vs. 103/402 (25.6%), = 0.003 or <0.0001 in a random or fixed-effects model, respectively; 14/296 (4.7%) vs. 26/183 (14.2%), = 0.001; and 4.6% (15/328) vs. 18.7% (23/123), = 0.0001, respectively).
The current single-center case series and systematic review with meta-analysis of studies demonstrated that surgical revascularization, including direct, indirect, and a combination of both, significantly reduces rebleeding, ischemic events, and mortality in HMMD patients in the East Asia region. More well-designed studies are warranted to further confirm these findings.
出血性烟雾病(HMMD)的最佳治疗方法仍是一个有争议的话题,尤其是关于血运重建与保守治疗的比较疗效。我们的研究包括单中心病例系列和系统评价及荟萃分析,旨在确定与东亚HMMD患者的保守治疗相比,手术血运重建是否与术后再出血、缺血事件和死亡率的显著降低相关。
我们通过检索PubMed、谷歌学术、万方医学在线(WMO)和中国知网(CNKI)进行了系统的文献综述。比较了手术血运重建和保守治疗的结果,包括再出血、缺血事件和死亡率。作者所在机构的24例患者系列也纳入分析并进行了回顾。
该研究共纳入了19项涉及1571例患者的东亚研究以及我们机构对24例患者的回顾性研究。在仅针对成年患者的研究中,接受血运重建的患者与接受保守治疗的患者相比,再出血、缺血事件和死亡率显著更低(分别为13.1%(46/352)对32.4%(82/253),<0.00001;4.0%(5/124)对14.9%(18/121),P = 0.007;3.3%(5/153)对12.6%(12/95),P = 0.01)。在成年/儿童患者的研究中,获得了关于再出血、缺血事件和死亡率的类似统计学结果(分别为70/588(11.9%)对103/402(25.6%),在随机或固定效应模型中P分别为0.003或<0.0001;14/296(4.7%)对26/183(14.2%),P = 0.001;4.6%(15/328)对18.7%(23/123),P = 0.0001)。
当前的单中心病例系列以及对研究的系统评价和荟萃分析表明,包括直接、间接及两者联合的手术血运重建显著降低了东亚地区HMMD患者的再出血、缺血事件和死亡率。需要更多设计良好的研究来进一步证实这些发现。